Normal Tissue Objective Parameter Optimization in Eclipse Treatment Planning System: Enhancing Stereotactic Radiosurgery Quality with Noncoplanar RapidArc versus HyperArc Plans

Eclipse治疗计划系统中正常组织目标参数优化:非共面RapidArc与HyperArc计划对比提升立体定向放射外科手术质量

阅读:1

Abstract

PURPOSE: The purpose of this study was to identify the most effective manual normal tissue objective (mNTO) parameters for noncoplanar RapidArc (RA) stereotactic radiosurgery (SRS) plans and assess their performance against HyperArc (HA) plans. MATERIALS AND METHODS: This retrospective study included 28 patients with single brain metastasis prescribed 21 Gy. Noncoplanar RA (RA-mNTO) plans were generated using dose fall-offs of 0.1-5.0 mm(-1) and end doses of 50%, 25%, and 10%. In addition, two HA plans were created for comparison: one with SRS NTO (HA-sNTO) and the other with mNTO (HA-mNTO). Plans were evaluated using an integrated scoring approach that include Paddick Conformity Index (CI), gradient index (GI), homogeneity index (HI), monitor units (MUs), normal brain doses (V(18 Gy), V(15 Gy), and V(12 Gy)), and delivery accuracy with aS1200 portal dosimetry applying 3%/1 mm gamma criteria. Statistical analysis was carried out using Wilcoxon signed-rank test. RESULTS: RA-mNTO plan with a 25% end-dose and a 0.5 mm(-1) dose fall-off significantly outperformed HA plans (P < 0.05) in CI, GI, and HI values (0.92 ± 0.02, 3.0 ± 0.17, and 0.32 ± 0.05 vs. 0.91 ± 0.04, 3.41 ± 0.19, and 0.40 ± 0.04 for HA-sNTO and 0.90 ± 0.04, 3.17 ± 0.24, and 0.40 ± 0.05 for HA-mNTO). Furthermore, RA-mNTO significantly (P < 0.05) reduced brain doses at V18Gy (0.88 cc ± 0.40), V15Gy (1.80 cc ± 0.77), and V12Gy (3.19 cc ± 1.35) compared to HA-sNTO (1.13 cc ± 0.51, 2.30 cc ± 1.01, 3.96 cc ± 1.72) and HA-mNTO (1.02 cc ± 0.44, 2.06 cc ± 0.86, 3.53 cc ± 1.47). Moreover, RA-mNTO showed significantly (P < 0.05) lower MUs (8238 ± 948) compared to HA-sNTO (9505 ± 1098) and HA-mNTO (9315 ± 421) and higher gamma pass rates (99.8% ± 0.39) than HA-sNTO (98.9% ± 0.68) and HA-mNTO (99.0% ± 0.51). CONCLUSION: Optimized mNTO (25% end-dose and a 0.5 mm(-1) dose fall-off)-based noncoplanar RA plans outperformed HA in SRS treatment of single brain metastasis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。